Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.
| Autor: | Shareef MS; Department of Dermatology, York Teaching Hospital, York, UK. m.shareef@nhs.net, Munro LR, Owen RG, Highet AS |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical and experimental dermatology [Clin Exp Dermatol] 2012 Mar; Vol. 37 (2), pp. 146-8. Date of Electronic Publication: 2011 Nov 21. |
| DOI: | 10.1111/j.1365-2230.2011.04219.x |
| Abstrakt: | Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma. (© The Author(s). CED © 2011 British Association of Dermatologists.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|